During the past decade, Tulane University Sickle Cell Center conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Tulane University Sickle Cell Center" are "Anemia, Sickle Cell" (1 trials), "Hemolytic Anemia" (1 trials), "Iron Overload" (1 trials) and "Sickle Cell Disease" (1 trials). Many other conditions were trialed in "Tulane University Sickle Cell Center" in a lesser frequency.

Most popular intervention types in "Tulane University Sickle Cell Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Deferasirox (ICL670)" (1 trials), "Deferoxamine (DFO)" (1 trials) and "ICL670, deferoxamine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Tulane University Sickle Cell Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Tulane University Sickle Cell Center". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Tulane University Sickle Cell Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Tulane University Sickle Cell Center, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".